Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Gilead Sciences : COVID SCIENCE-Protein found on infected cells protects virus from immune system; remdesivir helps prevent hospitalization

09/27/2021 | 03:08pm EDT

Sept 27 (Reuters) - The following is a summary of some recent studies on COVID-19. They include research that warrants further study to corroborate the findings and that have yet to be certified by peer review.

Virus-infected cells protected from immune system by protein

A protein called CD47 that helps damaged cells avoid destruction by the immune system may be contributing to severe cases of COVID-19, researchers believe. Drugs in development targeting CD47 may result in improved COVID-19 therapies, they suggested in a report published in Current Issues in Molecular Biology https://bit.ly/3COZyvb. "We may have identified a major factor associated with severe COVID-19," coauthor Martin Michaelis of the University of Kent said in a statement. "We can now look forward to further progress in the design of therapeutics." In lab experiments, the researchers found that CD47 - which in effect tells the immune system, "Do not eat me!" - is present in increased amounts on the surfaces of cells infected with the coronavirus. SARS-CoV-2 infection also increases levels of another protein, SIRPalpha, that partners with CD47 to trick the immune system into ignoring the sick cells. Previous studies have shown that CD47 levels are also elevated in conditions that put people at higher risk for critical illness from COVID-19, such as old age, diabetes, high blood pressure, and clogged blood vessels. In these groups, "high CD47 levels may predispose... to severe COVID-19," the researchers said. "Further research will be needed to define the roles of CD47 and/or SIRPalpha in COVID-19 in more detail," they added.

Remdesivir keeps high-risk patients out of the hospital

Gilead Sciences Inc's intravenous antiviral drug remdesivir helped keep high-risk COVID-19 patients out of the hospital in a randomized trial, the company announced https://bit.ly/2XMyc9X. The 562 patients in the study all had conditions that increased their risk for becoming critically ill. Half received three days of treatment with remdesivir - sold under the brand name Veklury - while the rest received a placebo. Four weeks later, 5.3% of patients in the placebo group had been hospitalized or died, compared to 0.7% of those who received remdesivir. That translated into an 87% lower risk of hospitalization or death. Remdesivir-treated patients also had significantly fewer medical visits, the company said. The drug is currently authorized for emergency use in hospitalized patients. "These latest data show remdesivir's potential to help high-risk patients recover before they get sicker and stay out of the hospital altogether," study leader Dr. Robert Gottlieb of Baylor University Medical Center said in a statement. His team plans to formally report the data at an upcoming medical conference.

Pandemic cuts life expectancy by most since WWII

The COVID-19 pandemic has reduced life expectancy in 2020 by the largest amount since World War II, with the life expectancy of American men dropping by more than two years, according to new data. In the 29 countries studied - the United States, Chile, and 27 in Europe - all but two showed reductions in life expectancy. There were greater drops in life expectancy for men than women in most countries. "The large declines in life expectancy observed in the United States can partly be explained by the notable increase in mortality at working ages observed in 2020," study co-leader Ridhi Kashyap of the University of Oxford said in a statement. "In the United States, increases in mortality in the under 60 age group contributed most significantly to life expectancy declines, whereas across most of Europe increases in mortality above age 60 contributed more significantly." The largest declines were found in U.S. men, who saw life expectancy drop by 2.2 years relative to 2019, followed by a 1.7-year decline for Lithuanian men. Women in the United States and Spain had drops in life expectancy of 1.5 years or more. Overall, men had more than a year shaved off in 15 countries, compared to women in 11 countries. Females from 15 countries and males from 10 ended up with lower life expectancy at birth in 2020 than in 2015, the research team reported on Sunday in the International Journal of Epidemiology https://bit.ly/3kKLYmr.

Click for a Reuters graphic https://tmsnrt.rs/3c7R3Bl on vaccines in development.

(Reporting by Nancy Lapid and Victor Jack; Editing by Bill Berkrot)

© Reuters 2021
All news about GILEAD SCIENCES, INC.
07:38aGILEAD SCIENCES : Presents Long-Term Switch Data Reinforcing Biktarvy® as a Treatment Opti..
07:17aGILEAD SCIENCES : Announces Decision Not to Pursue Marketing Authorization for Descovy for..
10/20GILEAD SCIENCES : Announces Decision Not to Pursue Marketing Authorization for Descovy® fo..
10/19Atea plunges after COVID-19 treatment fails to help patients in study
10/19GILEAD SCIENCES : to Donate 103,000 Vials of Veklury to Indonesia, Armenia
10/19GILEAD SCIENCES : Announces Veklury® Donations to Help Address the Ongoing COVID-19 Crisis..
10/19GILEAD SCIENCES : U.S. Food and Drug Administration Approves Expanded Indication of Gilead..
10/18GILEAD SCIENCES : Secures FDA Approval for Expanded Indication of Biktarvy for Treatment o..
10/18GILEAD SCIENCES : U.S. Food and Drug Administration Approves Expanded Indication of Gilead..
10/18Gilead Sciences, Inc. Announces the U.S. FDA Approves a New Low-Dose Tablet Dosage form..
More news
Analyst Recommendations on GILEAD SCIENCES, INC.
More recommendations
Financials (USD)
Sales 2021 25 188 M - -
Net income 2021 6 427 M - -
Net Debt 2021 23 041 M - -
P/E ratio 2021 13,3x
Yield 2021 4,22%
Capitalization 83 830 M 83 830 M -
EV / Sales 2021 4,24x
EV / Sales 2022 4,19x
Nbr of Employees 13 600
Free-Float 99,9%
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GILEAD SCIENCES, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 27
Last Close Price 66,86 $
Average target price 76,35 $
Spread / Average Target 14,2%
EPS Revisions
Managers and Directors
Daniel P. O'Day Chairman & Chief Executive Officer
Andrew D. Dickinson Chief Financial Officer
Merdad V. Parsey Chief Medical Officer
Flavius Martin Executive Vice President-Research
Brett A. Pletcher Secretary, Chief Compliance Officer & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
BIONTECH SE230.50%65 071
WUXI APPTEC CO., LTD.25.77%64 894
BEIGENE, LTD.44.20%34 774